Business Wire·Dec 3, 2025, 8:00 AM ET

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

BIAF BIAFW

bioAffinity Technologies, Inc. announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) on December 8, 2025.
The poster showcases three cases where CyPath® Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical & diagnostically challenging presentations.
Dr. Downie highlighted that indeterminate pulmonary nodules create clinical burdens when conflicting data exists, especially in patients with unusual risk profiles, discordant imaging, or advanced age.
In the presented cases, CyPath® Lung was used alongside low-dose CT, PET imaging, risk calculators, bronchoscopy, & blood serum markers to provide clarity & actionable results.
The NLCRT is a coalition of 194 organizations meeting December 8-9, 2025, at the Grand Hyatt Atlanta to reduce lung cancer mortality.
CyPath® Lung uses proprietary flow cytometry & artificial intelligence to identify malignancy-indicating cell populations in sputum via fluorescent porphyrin uptake.
Clinical study results demonstrated CyPath® Lung achieved 92% sensitivity, 87% specificity, & 88% accuracy in detecting lung cancer in high-risk patients with nodules under 20 millimeters.
bioAffinity Technologies markets CyPath® Lung as a Laboratory Developed Test (LDT) through its subsidiary, Precision Pathology Laboratory Services.
The press release includes standard forward-looking statement disclaimers regarding risks that could cause actual results to differ from expectations.